Adverse events on therapy plus 1 d (N = 302)
| Adverse events . | Patients, n (%) . |
|---|---|
| Any AE | 277 (92) |
| AEs occurring in 10% or more patients | |
| Headache | 86 (28) |
| Nasopharyngitis | 74 (25) |
| Upper respiratory tract infection | 69 (23) |
| Fatigue | 50 (17) |
| Diarrhea | 47 (16) |
| Arthralgia | 45 (15) |
| Back pain | 40 (13) |
| Urinary tract infection | 34 (11) |
| Nausea | 34 (11) |
| Cough | 32 (11) |
| Influenza | 30 (10) |
| Anemia | 29 (10) |
| Any SAE | 96 (32) |
| SAEs occurring in 4 (≥1%) or more patients | |
| Cataracts* | 16 (5) |
| Pneumonia | 8 (3) |
| Anemia | 5 (2) |
| ALT increase | 5 (2) |
| Epistaxis | 4 (1) |
| AST increase | 4 (1) |
| Bilirubin increase | 4 (1) |
| Deep vein thrombosis | 4 (1)† |
| Adverse events . | Patients, n (%) . |
|---|---|
| Any AE | 277 (92) |
| AEs occurring in 10% or more patients | |
| Headache | 86 (28) |
| Nasopharyngitis | 74 (25) |
| Upper respiratory tract infection | 69 (23) |
| Fatigue | 50 (17) |
| Diarrhea | 47 (16) |
| Arthralgia | 45 (15) |
| Back pain | 40 (13) |
| Urinary tract infection | 34 (11) |
| Nausea | 34 (11) |
| Cough | 32 (11) |
| Influenza | 30 (10) |
| Anemia | 29 (10) |
| Any SAE | 96 (32) |
| SAEs occurring in 4 (≥1%) or more patients | |
| Cataracts* | 16 (5) |
| Pneumonia | 8 (3) |
| Anemia | 5 (2) |
| ALT increase | 5 (2) |
| Epistaxis | 4 (1) |
| AST increase | 4 (1) |
| Bilirubin increase | 4 (1) |
| Deep vein thrombosis | 4 (1)† |